Cymerus MSCs for Neonatal Stroke, page-8

You wrote, "Obviously the plan did not go well."
Care to share what makes you think that the plan did not go well?


I also noticed your comment about our "mob" 's P1 trial over on the other thread:

https://hotcopper.com.au/threads/banter-and-general-discussion.5410558/page-4718?post_id=63726744

Any chance you could provide a link that shows a comment about Cohort B showing a clinical response on day 3?

I can see that participants had a study visit on day 3 according to the trial design:


https://clinicaltrials.gov/ct2/show/NCT02923375

But I can't see any mention of data being collected and/or presented for that timepoint later on.


Your post also mentions, "What did your boss say about why they would go for the high dose?"
https://hotcopper.com.au/threads/banter-and-general-discussion.5410558/page-4724?post_id=63727240

I know what Kilian Kelly said:


https://app.sharelinktechnologies.com/announcement/asx/176993991ab6cb44f055a76242029f9d

This is an observation that is in line with Galiepau's findings:


https://www.cell.com/cell-stem-cell/pdfExtended/S1934-5909(18)30222-4

It therefore makes sense to use the higher dose which showed a "much quicker treatment response" early on. However, having data as early as day 3 would be very interesting to see as it would allow us to break down the provided data even further, even more than the published article in Nature has done.
https://www.nature.com/articles/s41591-020-1050-x